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Background: Upon inflammation, myeloid cell generation in the bone marrow (BM) is broadly enhanced by the
action of induced cytokines which are produced locally and at multiple sites throughout the body.
Methods: Using microarray studies, we found that Angptl4 is upregulated in the BM during systemic inflammation.
Results: Recombinant murine Angptl4 (rmAngptl4) stimulated the proliferation of myeloid colony-forming units (CFUs)
in vitro. Upon repeated in vivo injections, rmAngptl4 increased BM progenitor cell frequency and this was paralleled
by a relative increase in phenotypically defined granulocyte-macrophage progenitors (GMPs). Furthermore,
in vivo treatment with rmAngptl4 resulted in elevated platelet counts in steady-state mice while allowing a
significant acceleration of reconstitution of platelets after myelosuppressive therapy. The administration of
rmAngptl4 increased the number of CD61+CD41low-expressing megakaryocytes (MK) in the BM of steady-state
and in the spleen of transplanted mice. Furthermore, rmAngptl4 improved the in vitro differentiation of immature
MKs from hematopoietic stem and progenitor cells. Mechanistically, using a signal transducer and activator of
transcription 3 (STAT3) reporter knockin model, we show that rmAngptl4 induces de novo STAT3 expression in
immature MK which could be important for the effective expansion of MKs after myelosuppressive therapy.
Conclusion: Whereas the definitive role of Angptl4 in mediating the effects of lipopolysaccharide (LPS) on the
BM has to be demonstrated by further studies involving multiple cytokine knockouts, our data suggest that
Angptl4 plays a critical role during hematopoietic, especially megakaryopoietic, reconstitution following stem cell
transplantation.
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Hematopoiesis is a tightly regulated process that leads
to the well-balanced production of myeloid, erythroid,
and lymphoid cells from a small number of highly pro-
liferative hematopoietic stem and progenitor cells
(HSCs and HPCs) [1]. During steady-state conditions,
hematopoiesis is controlled by the coordinated action
of a complex interplay of supporting growth factors
and the signals they deliver through hematopoietic
cytokine receptors expressed at the surface of HSPCs
[2, 3]. These growth factors are produced in the bone
marrow (BM) microenvironment or at multiple sites
throughout the body from where they reach their target
cells in the BM via the bloodstream [2, 4]. Broadly acting
early cytokines, including interleukin (IL)-1, IL2, IL-3, IL-6,
and IL-11, enhance the initial stages of hematopoietic de-
velopment and can be distinguished from more late-acting
hematopoietic differentiation-inducing cytokines like gran-
ulocyte colony-stimulating factor (G-CSF), macrophage
colony-stimulating factor (M-CSF), and granulocyte-
macrophage colony-stimulating factor (GM-CSF) [4].
Pattern recognition receptors like Toll-like receptors
(especially TLRs 4, 7, and 9) recognize conserved mi-
crobial products derived from exogenous pathogens [5].
Inflammatory conditions like bacterial or viral infections
increase the production and release of early- and late-
acting hematopoietic cytokines, and these cytokines
contribute to the rapid replenishment of consumed
innate immune effector cells like granulocytes and
macrophages [6]. As a result, early hematopoiesis in the
BM is significantly skewed towards myeloid cell differenti-
ation and output, leading to an increase of myeloid
colony-forming progenitor cells as well as granulocytes in
the circulation, a process that is described as emergency
myelopoiesis [7, 8]. In response to gram-negative infec-
tions, emergency myelopoiesis is mediated by TLR4-
expressing non-hematopoietic cells, which sense systemic
lipopolysaccharide and by secreting myeloid cytokines
such as G-CSF, induce an adequate myelopoietic response
within the BM [9].
The involvement of different cytokines such as G-CSF,
GM-CSF, or IL-6 in regulating hematopoiesis during
steady states as well as during emergency situations has
been shown: respective knockout mice have defects both
in production and function of myelopoietic effector cells
[10–12]. However, alternative pathways are likely to exist
as mice with single or combined deficiencies for G-CSF,
GM-CSF, and IL-6 or G-CSF and GM-CSF are still able
to mount reactive myelopoietic responses during inflam-
matory conditions [10, 12–14].
The goal of this study was the identification of novel
cytokines with yet unknown function in the hematopoietic
system. We therefore analyzed the BM of lipopolysacchar-
ide (LPS)- and vehicle-injected wild-type (WT) mice bygene expression microarray. Among the known candi-
dates, we identified angiopoietin-like 4 (Angptl4) as a
predominantly upregulated protein in the BM during
inflammatory conditions. Angptl4 has a broad range
of activities on hematopoiesis acting both on early
hematopoietic progenitors as well as on immature
CD61+CD41low-expressing megakaryocytes (MKs). Further-
more, Angptl4 is a potent stimulator of megakaryopoiesis
after myelosuppressive therapy.
Materials and methods
RT-qPCR
For the isolation of RNA, tissue samples were homoge-
nized in TRIzol reagent using a bead beater homogenizer
(PEQLAB, Erlangen, Germany). All cell samples were
lysed in TRIzol reagent, and RNA was purified according
to the manufacturer’s instructions (Invitrogen, Carlsbad,
USA). All RNA samples were subjected to DNAse I treat-
ment. cDNA was synthesized using random hexamers pri-
mer and Superscript III reverse transcriptase according to
the manufacturer’s instructions (Invitrogen, Carlsbad, CA,
USA). For all expression experiments, 100 ng cDNA each
was analyzed. Real-time PCR for Angptl4 and G-CSF
mRNA expression in the murine BM, liver, spleen, lung,
and bone marrow stromal cells, as well as PCR for friend
leukemia integration 1 (Fli-1), signal transducer and acti-
vator of transcription 3 (STAT3), and nuclear factor
erythroid-derived 2 (NF-E2) mRNA in MK cultures was
performed using a sequence detector (7500 Fast Real-
Time PCR System; Invitrogen) and TaqMan target mixes
(Assay-on-Demand Gene expression reagents; Invitrogen).
ELISA cytokine assay
Measurement of mouse G-CSF and Angptl4 was done in
serum of LPS vs. control mice according to the manufac-
turer’s instructions (G-CSF, R&D Systems, Minneapolis,
MN, USA; Angptl4, USCN Life Science, USA). BM
plasma from the control and LPS-injected mice was pre-
pared by flushing both femurs and tibia with 300 μl of
cold PBS into Eppendorf-type centrifuge tubes. Cells/
debris were removed by centrifugation at 3000 g for
10 min at 4 °C; BM plasma was stored at −20 °C. Con-
trol and LPS-stimulated bone marrow stromal cells
(BMSCs) at passage 1 were grown to confluence in a
T75 flask and kept for 48 h in 7 ml of Iscove’s Modified
Dulbecco’s Medium (IMDM) (GIBCO; Life Technologies,
Carlsbad, CA, USA) supplemented with 20 % FCS, 2 mM
L-glutamine, 50 nM 2-mercaptoethanol (all reagents from
Sigma-Aldrich, St. Louis, MO, USA), antibiotics (GIBCO;
Life Technologies, Carlsbad, CA, USA), and with or
without LPS (10 μg/ml) stimulation. Supernatants were
harvested, cleared by centrifugation, and passed through a
0.45 μm filter. Culture supernatants were analyzed for
G-CSF and Angptl4.
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To assess colony-forming unit (CFU) stimulation of
murine cytokines, freshly isolated mononuclear BM cells
(3 × 104) resuspended in IMDM and supplemented with
20 % FCS, 2 mM L-glutamine, 50 μM 2-mercaptoethanol,
stem cell factor (SCF; 10 ng/ml), fms-related tyrosine
kinase 3 (FLT3; 10 ng/ml), and thrombopoietin (TPO;
50 ng/ml) were mixed with methylcellulose (Methocult
M3231, 2.6 %, StemCell Technologies, Vancouver,
Canada) to yield a final concentration of 0.9 % methyl-
cellulose. Additional factors were added in the follow-
ing concentrations as indicated within the figure: IL-3
(20 ng/ml), GM-CSF (50 ng/ml), G-CSF (50 ng/ml), and
Angptl4 (50 ng/ml). For estimation of CFU frequency after
Angptl4 stimulation in vivo, 3 × 104 cells were plated
in methylcellulose mixed with IMDM (30 % FCS,
2 mM L-glutamine, 50 μM 2-mercaptoethanol) includ-
ing the following factors: mIL-3 (10 ng/ml), hIL-6
(10 ng/ml), mSCF (10 ng/ml), mGM-CSF (10 ng/ml),
mTPO (50 ng/ml), and huEPO (2 U/ml) (all R&D Systems,
Minneapolis, MN, USA).
Lethal irradiation and transplantation
Six- to ten-week-old female B6.SJL-PtprcaPep3b/BoyJ
mice were lethally irradiated with 2 × 6.5 Gy in a 4-h inter-
val and transplanted with 5 × 105 BM mononuclear cells
derived from syngeneic PBS, Angptl4, or non-injected
donor mice. All mice were maintained at the animal facil-
ity of the university clinic in Aachen, Germany. All animal
experiments were approved by the Federal Ministry for
Nature, Environment and Consumers’ Protection of the
state of North Rhine-Westphalia and were performed in
accordance to the respective national, federal, and institu-
tional regulations.
LPS and Angptl4 injection
For microarray and mRNA analysis, the mice were
injected once i.p. with 50 μg LPS (1:1 mixture of Escheri-
chia coli K12 and Salmonella minnesota) and analyzed
8 h later. For detection of BM plasma and blood serum
G-CSF and Angptl4 levels, the mice were injected twice
i.p. with 50 μg LPS in a 48-h interval and analyzed 24 h
later. Murine recombinant Angptl4 (250 μg/kg body
weight in 100 μl PBS) was injected i.p. for five consecu-
tive days, and the mice were analyzed 48 h later.
In vitro generation of murine megakaryocytes
MKs were developed from lineage-depleted BM cells. Lin+
was depleted from mononuclear cells using a lineage cell
depletion kit (Miltenyi, Bergisch Gladbach, Germany)
according to the manufacturer’s instructions. Lin− cells
were seeded at 1 × 105 cells per 1 ml in 48-well plates.
Cells were cultured in IMDM containing bovine serum
albumin, insulin, transferrin, SCF (25 ng/ml), and antibiotics.Where indicated, Angptl4 (30 ng/ml), TPO (30 ng/ml),
or both were added. Cultures were performed at 37 °C
in a fully humidified atmosphere of 5 % CO2. After
5 days of culture, cells were subjected to flow cytometry
analysis using CD41 (eBioMWReg30) and CD61 (209.G3)
antibodies, or smear preparations were prepared using
cytospin and stained by the Wright-Giemsa method.
Cell counting
Cells were counted using flow cytometry and Flow-Count
fluorospheres (Beckman Coulter, Brea, CA, USA). After
washing, harvested cells were resuspended in PBS contain-
ing 10 % FCS, 2 mM EDTA, and 7-aminoactinomycin D.
Immediately prior to analysis, 50 μl of Flow-Count
fluorospheres were added. Absolute cell counts were
automatically determined using a Gallios FACS
analyzer (Beckman Coulter, Brea, CA, USA). The
system software calculated cell numbers using the
following formula: cells per microliter = [(viable cells
counted)/(fluorospheres counted)] × fluorospheres/
microliter (see Additional file 1 for supplementary methods).
Results
Systemic inflammation regulates BM gene clusters
associated with immune system process and positive
regulation of cytokine production
In order to find cytokines which are broadly enhancing
myeloid cell regeneration, we analyzed the BM of the LPS-
and vehicle-injected WT mice (i.p.; single injection) using
oligonucleotide gene expression microarrays. Among 412
total genes, 326 were more than 1.5-fold and significantly
(p ≤ 0.05) upregulated (Fig. 1a). To identify enriched gene
ontology (GO) classes in any of the two differentially
expressed gene sets, GO analysis was performed on GO-
Elite using the gene ontology database [15, 16]. Biological
categories such as immune system process, regulation of
hydrolase activity, homeostatic process, and positive regu-
lation of cytokine production were significantly enriched
in the differentially expressed gene set, suggesting a gener-
alized activation of the BM in response to inflammatory
conditions (Fig. 1b). By focusing on the identification of
genes encoding for potential cytokines or membrane pro-
teins, we used signal peptide prediction algorithms to
identify signal peptides which direct surface expression
or secretion [17]. Among 116 predicted genes, 93 were
upregulated and 23 were downregulated after LPS
treatment (Fig. 1c). Among the known candidates,
Angptl4 [18–20] was a predominantly upregulated gene
in the BM of LPS-treated WT mice. Since previous
studies had already implicated a potential role of
angiopoietin-like family members affecting hematopoiesis
[21, 22], we focused on the characterization of Angptl4
expression during inflammatory conditions and its effects
on hematopoiesis in vitro and in vivo.
Fig. 1 Systemic inflammation regulates BM gene clusters associated with immune system process and positive regulation of cytokine production.
a Volcano plot for comparisons of BM cells isolated from LPS-treated (50 μg from 1:1 mixture of E. coli strain K12 and S. minnesota strain R595)
and PBS-treated mice. Each gene is represented by a dot in the graph. The x-axis represents the log2 value of fold change, and the y-axis represents the
t-statistic as log10 p value. Colored dots represent the genes that are regulated more or equal to 1.5 fold up (red, n = 326) or down (green, n = 86) with
an adjusted p value not higher than 0.05. b GO analysis of regulated genes after LPS treatment. Enriched terms found related to regulated
genes in biological processes (BP), operations, or sets of molecular events with a defined beginning and end and more than one distinct step.
The z-score threshold of >1.96 resulted in 149 enriched GO terms for BP. Only enriched BP terms that include either 30 % or 15 differentially
expressed genes are illustrated. c Heat map of differentially expressed genes predicted with the SignalP web server as cytokines or membrane
proteins. After LPS treatment, 93 candidates are found to be upregulated and 23 to be downregulated. Genes are ordered in rows and samples in
columns. The expression levels are coded as indicated in the color key. Shades of green and red refer to the differential expression levels as log2 fold
values, as indicated in the color key
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To see if inflammatory signals translate into increased
Angptl4 production at the protein level, we stained the
BM sections of the WT and TLR-4−/−mice from the LPS-
injected mice as well as the control injected WT mice with
an antibody against Angptl4 (Fig. 2a). Strong Angptl4-
positive cells were detected in the BM of the LPS-injected
mice exclusively, including both non-hematopoietic stro-
mal and endothelial cells as well as cells of hematopoietic
origin as determined by morphological examination. We
further evaluated Angptl4 upregulation during inflamma-
tory conditions in comparison with G-CSF by qRT-PCR.
We focused on G-CSF because during LPS-mediatedinflammatory responses such as bacterial-induced in-
flammation or sepsis, G-CSF is heavily released albeit
only detected on low levels in steady-state conditions
[7, 8]. While G-csf mRNA was detectable in the total
tissue extracts at low levels in steady-state spleen and
lung which is in accordance with previous studies [23],
this was initially not the case in the liver and BM
(Fig. 2b and Additional file 2: Fig. S1A). However, at
8 h after i.p. LPS injection, G-csf mRNA expression was
significantly upregulated in the BM, the primary sites
of myelopoietic cell production, and in the liver as well
as in the spleen and lung, sites of myelopoietic migra-
tion and activation (Additional file 2: Fig. S1A). Angptl4
mRNA was detected at the baseline in the steady-state
Fig. 2 Angptl4 is upregulated in the BM of mice during inflammatory conditions. a Hematoxylin-eosin staining and Angptl4 expression in
BM sections from WT and TLR-4−/− mice at 72 h after double PBS or LPS (50 μg from 1:1 mixture of E. coli strain K12 and S. minnesota strain
R595) injections. Sections were either labeled with anti-Angptl4 antibody (right panel) or isotype-matched antibodies (left panel). Original
magnification ×200. b G-csf and Angptl4 mRNA expression in the BM of PBS-treated (white bars) or LPS-treated (gray bars) WT mice. Expression levels
are normalized against 18 s RNA. Mice were i.p. injected once with 50 μg LPS and analyzed 8 h later. Mean ± SEM of three different experiments each
with a total of three PBS- and three LPS-injected mice/group are shown. c Blood and BM plasma G-CSF and Angptl4 protein levels in the PBS-treated
(white bars) or LPS-treated (gray bars) WT mice, treated as in a. Mean ± SEM of two different experiments with a total of five PBS-treated and
five LPS-treated mice are shown. d G-CSF and Angptl4 protein levels in supernatants at 48 h after single PBS (white bars) or LPS stimulation
(10 μg from 1:1 mixture of E. coli strain K12 and S. minnesota strain R595, gray bars) of BMSC cultures. Mean ± SEM of supernatants from three
experiments, each with different donor BMSCs, is shown. n.d. not detectable within the sensitivity of the assay, n.s. not significant within 35
cycles of amplification. Statistically significant differences are indicated (***p < 0.001)
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nificantly and most extensively upregulated in the BM
and lung and increased in the liver and spleen (Fig. 2b
and Additional file 2: Fig. S1A). In line with G-csf and
Angptl4 mRNA induction, a significant increase of G-
CSF and Angptl4 protein levels in BM plasma [24] was
observed at 72 h after LPS injection in the WT mice,
whereas in the vehicle-injected mice, G-CSF and
Angptl4 protein levels were not detected (Fig. 2c). Up-
regulation of G-CSF in BM plasma after LPS injectionwas paralleled by high levels of G-CSF in blood plasma,
whereas Angptl4 blood plasma levels were barely de-
tectable and not different from the controls.
As different pathogenic signals evoke different cellu-
lar responses, we additionally analyzed mice with
(Streptococcus pneumoniae) S.p.-induced experimental
meningitis. After S.p. injection through the frontolat-
eral skull, the mice have been shown to rapidly develop
gram-positive bacteremia and a systemic inflammatory
response [25], which is dependent on the activity of
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lyzed the BM of the S.p.-injected mice for emergency
myelopoiesis characteristic myeloid cell proliferation
and differentiation [9, 24, 29]. As in the LPS-injected
animals, mature myeloid cells (CD11b+Gr-1high) de-
creased upon S.p. injection, whereas the frequency of
promyelocytes and myelocytes (CD11b+Gr-1low) were
found to be increased (Additional file 2: Fig. S2A).
Compared to the vehicle-injected animals, the S.p.-
injected animals showed an increase of G-CSF and
Angptl4 both in BM and in blood plasma, respectively
(Additional file 2: Fig. S2B).
To identify the candidate producer cells of Angptl4 dur-
ing inflammatory conditions, we purified mouse bone
marrow stromal cells (BMSCs) from the BM by plastic ad-
herence. Stromal cultures, developed from proliferating
mesenchymal precursors, expressed stroma-associated
surface markers and could be differentiated into adipo-
cytes and osteoblasts (Additional file 2: Fig. S3A, B).
Stimulation of murine BMSC with LPS induced the pro-
duction of G-CSF and Angptl4 proteins, both of which
were barely detectable at the baseline (Fig. 2d). We con-
clude that systemic inflammatory conditions induce
Angptl4 mRNA expression at different sites throughout
the body including Angptl4 protein production and re-
lease in the BM, the primary site of hematopoiesis.
Angptl4 stimulates the proliferation of myeloid
progenitors in vitro and expands myeloid progenitors
in vivo
We first evaluated the in vitro effects of Angptl4 in mye-
loid CFU assays using murine BM cells (Fig. 3a). Treat-
ment of BM cells with Angptl4 enhanced colony
formation by approximately twofold, comparable to the
stimulating activity of G-CSF and GM-CSF in this assay.
Angptl4 did not further enhance the effects of IL-3
or G-CSF, alone or in combination. Treatment with
Angptl4 and GM-CSF had additive effects on colony for-
mation but this not further increased by the addition of
IL-3. We therefore conclude that Angptl4 has a selective
effect on colony formation towards a hematopoietic pro-
genitor with responsiveness to GM-CSF but not to G-
CSF. Next, we tested whether LPS-induced upregulation
of Angptl4 in the BM correlates with enhanced progeni-
tor cell growth and differentiation [30, 31] and examined
colony formation of unfractionated BM with combined
cytokines (SCF, TPO, IL-3, GM-CSF, IL-6, EPO) in vitro
after Angptl4 treatment in vivo (Fig. 3b). mrAngptl4 in-
creased triglyceride levels in peripheral blood [32] and
Angptl4 protein levels in the BM plasma of tail vein
injected mice, suggesting that injected Angptl4 was
functional and reached the BM cavity (Additional file 2:
Fig. S4A). Colony numbers of granulocyte-macrophage
progenitors (CFU-GM) were significantly increasedafter repeated Angptl4 injections, whereas the number
of multilineage colony-forming unit-granulocyte, erythro-
cyte, monocyte/macrophage, megakaryocyte (CFU-GEMM)
progenitors was reduced and the number of burst-forming
unit-erythroid (BFU-E) colonies did not significantly differ
between the Angptl4-treated and control animals. To deter-
mine whether the effects on colony formation recapitulates
in cell-surface-defined hematopoietic progenitor subsets,
we analyzed the impact of in vivo Angptl4 treatment on
various progenitor populations by flow cytometry (Fig. 3c).
While the number of granulocyte-macrophage progenitors
(GMPs) was increased after administration of Angptl4, MK
and erythrocyte lineage-restricted progenitors (MEPs) and
common myeloid progenitors (CMPs) have not been af-
fected (Fig. 3d). These data suggest that recombinant
Angptl4 stimulates the proliferation of myeloid CFUs
in vitro. In mice, repeated injections of Angptl4 increased
BM progenitor cell frequency, and this was paralleled by a
relative increase in phenotypically defined GMPs.
In vivo treatment with Angptl4 results in elevated platelet
counts in mice in steady state and after myelosuppressive
therapy
As we did not recognize an effect on overall cellularity
of the BM between the PBS- and Angptl4-treated ani-
mals, we went on to examine the effects of rmAngptl4
on more mature myeloid bone marrow cells by staining
BM sections with hematoxylin and eosin. We identified
local accumulations of dysplastic and immature MKs
(Fig. 4a). Immature MKs recently have been described as
a major population of MKs in murine BM and, based on
low CD41 expression and acetylcholinesterase (AChE)
activity, are defined as being Lin−/CD41+/CD45+/AChE−
[33]. In contrast, the more differentiated MKs are char-
acterized by a substantial AchE activity and higher expres-
sion levels of CD41. By applying flow cytometry after
surface staining on BM cells, we found within Lin−/CD45+
BM cells, CD61+CD41low and CD61+CD41high-expressing
MK subpopulations (Fig. 4b). Whereas the frequency of
total MK numbers and CD61+CD41high-expressing MK
subpopulations decreased after Angptl4 injection, the
frequency of CD61+CD41low-expressing MKs increased
significantly (Fig. 4b, c). The absolute numbers of MK
subpopulation after Angptl4 injection showed a similar
trend but did not reach significance with the number of
experiments performed.
Concomitantly, platelet (PLT) numbers were in-
creased in the Angptl4-injected mice (Fig. 4d) suggest-
ing an effect of Angptl4 specifically on the frequency of
CD61+CD41low-expressing MKs resulting in an acceler-
ation of differentiation during megakaryopoiesis. Acceler-
ation of megakaryopoiesis is believed to be the most
effective way to achieve a rapid recovery of PLT numbers
after cancer chemotherapy or stem cell transplantation
Fig. 3 Recombinant Angptl4 stimulates the proliferation of myeloid CFUs in vitro and expands myeloid progenitors in vivo. a CFU activity of 3 × 104
murine BM cells per well in the presence of SCF, TPO, and Flt3L. Addition of Angptl4, G-CSF, GM-CSF, and IL-3 as indicated. b CFU numbers per 3 × 104
seeded BM cells of the PBS-treated (white bars) or Angptl4-treated (gray bars) WT mice in the presence of the following cytokines: IL-3, IL-6,
SCF, GM-CSF, TPO, and EPO. Mice were daily injected with 250 μg/kg murine Angptl4 per kg body weight for five consecutive days. Mice were
analyzed 48 h after the last injection. Mean ± SEM of two different experiments with a total of six PBS-injected and six Angptl4-injected mice
are shown. c Representative FACS profiles of Lin− BM cells from the PBS- and Angptl4-injected WT mice. Lin− c-Kithigh Sca-1− cells were subdivided
into three subsets based on FcγRII/III and CD34 expression: CD34+FcγRII/III− (CMP), CD34+FcγRII/III+ (granulocyte/monocyte progenitors; GMP), and
CD34−FcγRII/III− (MEP). Numbers indicate percentages of total BM cells and fold changes of CD34+FcγRII/III+ fractions in the PBS- vs. Angptl4-treated
mice are shown. d GMP frequency as percentage of total cells, as well as total cell numbers in PBS- vs. Angptl-injected mice, treated as in b. Mean ± SEM
of three different experiments with three PBS-injected and three Angptl4-injected mice/group are shown. Statistically significant differences are indicated
(*p < 0.05, ***p < 0.001)
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have been shown to increase MK and PLT numbers after
transplantation of myelosuppressed animals [36–38]. We
therefore assessed the effect of Angptl4 injection on PLT
reconstitution after lethal irradiation and transplantation
of BM cells into recipient mice. Repetitive injections of re-
combinant Angptl4 for five consecutive days resulted in a
significantly accelerated reconstitution of PLTs starting at
day 8 after transplantation (Fig. 5a). The 50 % pre-
treatment PLT count was reached on day 14 in the
Angptl4-treated animals, as compared to day 21 for trans-
planted controls receiving no Angptl4. In contrast, we
were unable to detect differences in the reconstitutionlevels of erythrocytes and leucocytes between the Angptl4-
and PBS-injected animals at any time point examined
further supporting the specific effect of Angptl4 on mega-
karyopoiesis (Fig. 5a). The accelerated post-transplant re-
covery of PLTs after Angptl4 injection may be due to the
expansion of the number of megakaryocyte colony-
forming units (CFU-Meg) or may be related to effects
on more mature megakaryocytic progenitor cells. To
distinguish between these possibilities, we assessed the
effect on PLT reconstitution after transplantation of
in vivo Angptl4-modified BM cells. The donor mice
were treated with Angptl4 for five consecutive days,
and their BM was used for transplantation at day 7.
Fig. 4 In vivo treatment with Angptl4 increases immature megakaryocytes and results in elevated platelet counts. a Hematoxylin-eosin staining of BM
sections from PBS- or Angptl4-treated WT mice. Mice were daily injected with 250 μg/kg murine Angptl4 per kg body weight for five consecutive days
and analyzed 48 h after the last injection. The symbol “x” indicates MKs in the BM of PBS- and rmAngptl-treated mice, and arrows indicate
immature MKs in the BM of Angptl4-injected animals. One representative analysis from three independent experiments is shown. Magnification ×200.
b Representative FACS profile of Lin− BM cells from PBS- and Angptl4-injected WT mice. Lin−CD45+CD61+ cells were subdivided into three
subsets based on CD61 and CD41 expression: CD61+, CD61+CD41high, and CD61+CD41low cells. c Frequency and total cell numbers/tibia of
CD61+, CD61+CD41high, and CD61+CD41low cells. Mean ± SEM of three different experiments with three PBS-injected and three Angptl4-injected
mice/group are shown. d PLT counts from PBS- or Angptl4-treated WT mice. Mean ± SEM of three different experiments with three PBS-injected and
three Angptl4-injected mice/group are shown. Statistically significant differences are indicated (**p < 0.01)
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Fig. 5 Angptl4 accelerates the reconstitution of megakaryopoiesis after lethal irradiation and transplantation. a Reconstitution of PLTs, erythrocytes
(RBCs), and leucocytes (WBCs) after lethal irradiation (2 × 6.5 Gy) and transplantation of 1 × 105 BM cells. After transplantation, mice were daily injected
with PBS (shown in squares) or murine Angptl4 (shown in circles; 250 μg/kg body weight) for five consecutive days. Peripheral blood of transplanted
mice was collected every 3 days for a time course of 30 days, and PLT, RBC, and WBC counts were determined using an animal blood
counter. Each time point represents the mean of two different experiments with a total of ten mice/group. b PLT, RBC, and WBC counts after
lethal irradiation (2 × 6.5 Gy) and transplantation of 1 × 105 BM cells from Angptl4 (circles) or PBS (squares) pre-treated donor mice. Donor
mice were daily injected with PBS or Angptl4, as described in a and sacrificed 48 h after the last injection. After transplantation, peripheral blood was
collected and analyzed as described in a. Each time point represents the mean of two different experiments with a total of ten mice/group. c Frequency
and total cell numbers of CD61+, CD61+CD41high, and CD61+CD41low cells in the spleen at day 30 after transplantation. Recipient mice were
treated with Angptl4 after transplantation, as described in a. Mean ± SEM of three different experiments with three PBS-injected (white bars)
and three Angptl4-injected (gray bars) mice/group are shown. d Frequency and total cell numbers of CD61+, CD61+CD41high, and CD61+CD41low cells in
the BM at day 30 after transplantation. Recipient mice were treated with Angptl4 after transplantation, as described in a. Mean ± SEM of three different
experiments with three PBS-injected (white bars) and three Angptl4-injected (gray bars) mice/group are shown. (*p < 0.05, **p< 0.01)
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from the PBS pre-treated donor mice (Fig. 5b). As com-
pared to the control animals, in vivo modification of
donor BM with Angptl4 did not result in an accelerated
reconstitution of PLT numbers. This suggests that an
effect of Angptl4 at the level of CFU-Meg seems very
unlikely. Instead, we believe that Angptl4 specifically accel-
erates the differentiation process of MKs. In line with this,
we found significantly increased relative cell numbers ofCD61+CD41low cells in the spleen of the post-transplanted
Angptl4-treated mice (Fig. 5c) and this was recapitulated
with a non-significant trend in absolute cell numbers. It
has previously been shown that after lethal irradiation and
transplantation, donor-derived megakaryopoiesis occurs in
the spleen at higher densities than in the BM [39]. In line
with this observation, a post-transplant effect of Angptl4
on CD61+CD41low- and CD61+CD41high-expressing MKs
within the BM was not detected (Fig. 5d).
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megakaryocytes in vitro
To see if Angptl4 has impact on megakaryopoiesis in vitro,
we generated MKs by a serum-free liquid culture system of
enriched BM hematopoietic stem and progenitor cells in
the presence of SCF and the addition of TPO, Angptl4, or
combined TPO and Angptl4. Based on surface staining and
flow cytometry, we distinguished CD61+CD41low/negative
megakaryocytic lineage cells from CD61+CD41high mega-
karyocytic lineage cells (Fig. 6a). After 5 days of culture, the
addition of Angptl4 or TPO increased total cell numbers as
compared to culture with SCF alone, with the highest cell
numbers recovered from combined Angptl4 and TPO
cultures. CD61+CD41low/negative as well as CD61+CD41high
MK lineage cell numbers were increased in bothFig. 6 Angptl4 increases the number of CD61 + CD41low/negative MKs in vitro. a
CD61−CD41− cells in SCF-, SCF + TPO-, SCF + Angptl4-, and SCF + TPO + Angpt
Lin− BM cells. b Total cells developed and total number of CD61+CD41low
described in a. Mean ± SEM of three different experiments with a total of
and TPO-supplemented cultures are shown. Statistically significant differe
cytospin preparation and Wright-Giemsa staining of MK cultures as describedAngptl4-supplemented cultures above levels obtained
with SCF only (Fig. 6b). The effect on the development
of CD61+CD41low/negative cells was comparable between
Angptl4- or TPO-supplemented cultures, whereas the
Angptl4 effect on CD61+CD41high cells was much lower
(Fig. 6b). In addition, additive effects in Angptl4- and
TPO-combined cultures could be observed both on the
development of CD61+CD41high MKs as well as on the
development of CD61+CD41low/negative cells (Fig. 6b).
This suggests that Angptl4 and TPO expand immature
CD61+CD41low/negative cells and that, in Angptl4 and TPO
combination cultures, the expanded CD61+CD41low/negative
cells are responsive to differentiation induced by TPO. In
line with previous reports [40], we found terminally differ-
entiated MKs including cytoplasmic maturation andRepresentative FACS profile of CD61+CD41+, CD61+CD41low/negative, and
l4-supplemented cultures at day 5 after initiating cultures from 1 × 105
/negative and CD61+CD41+ cells in cytokine-supplemented cultures as
12 SCF-; 12 SCF and TPO-; 12 SCF and Angptl4-; and 12 SCF, Anptl4,
nces are indicated (*p < 0.05, **p < 0.01, ***p < 0.001). c Representative
in a. Original magnification ×400
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As shown by cytospin preparation and Wright-Giemsa
staining, TPO-supplemented cultures developed large,
smooth MKs, whereas in the absence of TPO, small
and medium size cells could be found. This data sug-
gest that Angptl4 increases immature megakaryopoietic
progenitor cell numbers in vitro but that it has no ef-
fect on terminal differentiation of MKs including cyto-
plasmic maturation.
Angptl4 induces de novo STAT3 expression in
CD61+CD41low/negative megakaryocytes in vitro
MK maturation is governed by the activity of a group of
transcription factors, including GATA-1, ETS family
members, NF-E2, and STAT3 [41, 42]. To investigate
the relative mRNA expression levels of transcription fac-
tors associated with different stages of MK differenti-
ation in response to Angptl4, we chose the ETS family
member Fli-1 [43–45], STAT3 [46, 47], NF-E2 [48], and
the GATA binding protein GATA-1. NF-E2 expression is
associated with late cytoplasmic maturation stages of
MK development [49]; Fli-1 and STAT3 are believed to
be expressed on MK precursors through the promega-
karyoblast stage with additional expression of STAT3 in
mature megakaryocytes and platelets [46, 47, 50, 51].
GATA-1 has been shown to promote MK differentiation
and to restrain abnormal immature MK expansion [52].
Fli-1 and STAT3 mRNA expression levels were both
induced by recombinant Angptl4 as well as TPO, con-
firming an involvement of Angptl4 during early develop-
mental stages of MK differentiation (Fig. 7a). In contrast,
an increase in NF-E2 mRNA expression could only be
found in TPO-supplemented cultures which is in line
with a lack of effect of Angptl4 in late cytoplasmic mat-
uration stages of MK development. Similarly, when we
analyzed GATA-1 mRNA, GATA-1 expression increased
to very high levels in the presence of TPO (Fig. 7a TPO).
We additionally analyzed GATA-1 and STAT3 in Angptl4-
supplemented “immature” cultures by confocal microscopy
and found GATA-1 in contrast to STAT3 barely detectable
(Additional file 2: Fig. S5D; immature/Angptl4). In line
with mRNA expression data, GATA-1 detection increased
in mature MKs.
Therefore, the expression levels for Fli-1, STAT3, NF-E2,
and GATA-1 mRNA reflect whether the culture contains
mainly immature or mature MKs.
It was shown that GATA-1 could bind and inhibit the
activity of STAT3 in MKs [52] and that the transgenic
expression of dominant negative STAT3 causes a signifi-
cant delay in PLT recovery after myelosuppression, sug-
gesting that STAT3 is required for normal regulation of
megakaryopoiesis [47]. We therefore focused on STAT3
to determine the effects of Angptl4 on this transcription
factor in more detail. To confirm that upregulation ofSTAT3 mRNA levels by Angptl4 faithfully reflects in-
creased STAT3 protein levels and to identify STAT3 ex-
pression in megakaryocytic and non-megakaryocytic
lineage cells in culture, we made use of a mouse model
with STAT3-yellow fluorescent protein (YFP) knocked
into the endogenous STAT3 locus. The mice bearing
the STAT3-YFP knockin allele develop normally are
fertile and display normal development of different
myeloid lineages, such as monocytes, granulocytes, and
MKs (data not shown). By measuring YFP, we assessed
the expression of STAT3 in MK cultures at day 5 after
initiating from Lin−/STAT3-YFP BM cells. In all
cytokine-supplemented cultures, STAT3+ cells devel-
oped with relative number varying between 15–60 %
(Additional file 2: Fig. S4A, B and data not shown) and
CD61+CD41low/negative megakaryocytic lineage cells as
well as CD61+CD41high megakaryocytic lineage cells
could be identified. In non-megakaryocytic lineage cells
defined by the lack of CD61 and CD41 surface staining,
STAT3+ cells were not detected, suggesting a restric-
tion of STAT3 expression to developing megakaryocytic
lineage cells in these cultures (Fig. 7b, c). In line with
that, STAT3 expression could be clearly detected in
CD61+CD41low/negative as well as CD61+CD41high-ex-
pressing cells (Fig. 7c). In CD61+CD41low/negative cells,
Angptl4 increased and at the same time TPO decreased
the fraction of STAT3+ cells. In CD61+CD41high cells,
TPO increased the percentage of STAT3+ cells whereas
Angptl4 had no additional effect. The number of
STAT3+ cells therefore reflects STAT3 mRNA levels
and further supports the impact of Angptl4 action
towards immature megakaryocytic lineage cells.
Discussion
In this study, we identified Angptl4 as an upregulated
protein during inflammatory conditions in the BM of
mice and determined the effects of recombinant Angptl4
on early and late stages of hematopoieisis in vitro and
in vivo. Angptl4 is a secreted glycoprotein with a physio-
logical role in lipid metabolism and a predominant ex-
pression in adipose tissue and liver [20, 53, 54]. Angptl4
inhibits the activity of lipoprotein lipase and thereby
promotes an increase in circulating triglyceride levels
[32, 55, 56]. Further involvement of Angptl4 has been
shown to occur in energy homeostasis, wound repair,
tumorigenesis, angiogenesis, and redox regulation [53].
As a member of the superfamily of Angptl proteins (in-
cluding Angptl 1–7), Angptl4 shares sequence homology
with angiopoietins and consists of a secretory signal pep-
tide, an N-terminal coiled-coil domain, and a C-terminal
fibrinogen-like domain [53]. In close correlation to our
data, upregulation of Angptl4 expression has been
shown during acute phase responses in the LPS-treated
mice in the liver, heart, muscle, and adipose tissue [57].
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tribute to hypertriglyceridemia, which is associated with
inflammation; however, a direct effect of Angptl4 on in-
flammatory pathways has not been demonstrated so far.
We here connect inflammation-induced upregulation ofFig. 7 Angptl4 induces de novo STAT3 expression in CD61+CD41low/negative M
NF-E2, and GATA-1 in SCF-, SCF + TPO-, SCF + Angptl4-, and SCF + TPO + Ang
Lin− BM cells. Mean ± SEM of three different experiments with a total of 12 SC
TPO-supplemented cultures are shown. Statistically significant differences
FACS profile and gating strategy for the detection of STAT3 expression o
cytokine-supplemented cultures at day 5 after initiating cultures from 1 × 105
knockin mice; lower panel: initiating cells stem from WT mice. Statistically signAngptl4 with the first hallmark of emergency myelopoiesis:
the increase of myeloid progenitors in the BM. However,
as LPS induces the production of a variety of different
cytokines and multiple cytokines display redundant func-
tions on hematopoiesis, the definitive role of Angptl4 inKs in vitro. a mRNA expression of the transcription factors Fli-1, STAT3,
ptl4-supplemented cultures at day 5 after initiating cultures from 1 × 105
F-; 12 SCF and TPO-; 12 SCF and Angptl4-; and 12 SCF, Angptl4, and
are indicated (*p < 0.05, **p < 0.01, ***p < 0.001). b, c Representative
f CD61−CD41−, CD61+CD41low/negative, and CD61+CD41high cells in
Lin− BM cells. c Upper panel: initiating cells are purified from STAT3-YFP
ificant differences are indicated (*p < 0.05, **p < 0.01, ***p < 0.001)
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strated by combining multiple cytokine knockouts.
Members of the angiopoietin-like family of proteins,
including Angptl4, have been shown to bind to paired
immunoglobulin-like receptors, which supports ex vivo
expansion of HSCs [21]. Remarkably, Angptl4 did not ef-
fectively stimulate expansion of HSCs. When trans-
planted into conditioned mice, Angptl4 expanded HSCs
and supported engraftment for 4 weeks only; however,
such effects were not detected 3 or 6 months after trans-
plantation [21]. These findings imply that Angptl4 might
have effects on committed progenitor cells rather than
on immature self-renewing HSCs. Indeed, our results
show that Angptl4 can regulate myeloid cell proliferation
at the level of HPCs, and Angptl4 therefore should be
added to the growing list of early-acting cytokines
such as IL-3 and IL-6. Interestingly, Angptl4, G-CSF,
and GM-CSF were equally active in enhancing agents
for murine BM colony formation in the presence of
SCF, TPO, and Flt3L in vitro. However, when com-
bined, Angptl4 had additive effects with GM-CSF but
not with G-CSF to increase colony formation. The
mechanism for this action is not known but may in-
volve an increased sensitivity of CFUs to Angptl4 or
GM-CSF through receptor upregulation or maturation
of progenitors.
In contrast to the action of G-CSF, Angptl4 seems to
have more local and limited effects. As the receptor of
G-CSF is expressed throughout the granulocytic lineage
from granulocytic precursors to mature neutrophils, its
increase in the blood has an immediate impact on gran-
ulopoiesis [4]. A massive increase in G-CSF upon LPS
stimulation is therefore, as a single cytokine, sufficient to
translate into leukocytosis and neutrophilia, which is
observed during emergency myelopoiesis [9]. Angptl4 has
been shown to be regulated by hypoxia and chronic
inflammatory responses. Angptl4 functions as a matricel-
lular protein and by inhibiting lipoprotein lipase (LPL),
Angptl4 increases serum trigylceride levels [57]. Although
Angplt 4 is seen as a physiological mediator of intracellu-
lar adipose tissue lipolysis, serum Angptl4 levels do not
always correlate with plasma triglyceride levels [58]. It has
already been demonstrated that hematopoietic stem cells
(HSCs) express PIRB, and PIRB therefore may function as
sensor of inflammation through binding to the inflamma-
tory Angptl4 and protecting HSCs from excessive activation
and exhaustion [59].
To see if Angptl4 has any in vivo action, we injected
mrAngptl4 into the WT mice for five consecutive days.
At the level of progenitor cells, the results obtained
showed that in vivo application stimulates the same
types of HPCs as are stimulated in vitro by mrAngptl4.
However, the effects seen after mrAngptl4 injection were
relatively moderate and did not result in a significantincrease of white blood cell counts. In addition, we directly
assessed the effects on myeloid cells after mrAngptl4
in vivo injection as compared to LPS injection. Whereas
LPS treatment clearly induced an increase in promyelo-
cytes and myelocytes in vivo, repeated Angptl4 injection
had only a marginal effect on the induction of metamyelo-
cytes and band forms (data not shown). We therefore con-
clude that Angptl4 might be involved in the fine-tuning of
proliferation and differentiation of leukocytes at the level
of their progenitors.
In vivo mrAngptl4 applications further lead to an in-
crease of peripheral blood PLTs and an increase of imma-
ture MKs in the BM, whereas phenotypically defined
MEPs were not affected. In addition, when applied after le-
thal irradiation and transplantation, mrAngptl4 treatment
resulted in a significantly accelerated recovery of PLTs,
whereas the transplantation of mrAngptl4 in the in vivo
pre-treated BM cells did not, suggesting that Angptl4 ex-
erts its effects mainly on immature MKs downstream of
CFU-Meg. In line with that, cytokines, which have been
shown to be capable of modifying murine BM cells to ac-
celerate PLT reconstitution after transplantation, such as
IL-6 and TPO [36–38], also have been shown to stimulate
and/or expand CFU-Meg formation in murine cultures
and in vivo. Therefore, it is tempting to speculate that
Angptl4 induces platelet production through the inter-
action with monopotent megakaryocyte-committed
progenitors (MKPs) [60]. Common myeloid progeni-
tors (CMP) and megakaryocyte-erythrocyte progenitors
(MEPs) can differentiate into MKPs after 72 h in stro-
mal cultures, indicating that MKPs are downstream of
these two progenitors. MKPs are cytokine responsive
progenitor cells, which do not display self-renewal activity
and therefore give rise to platelets for approximately
3 weeks [60]. When we analyzed c-kit+Sca-1−CD150+
CD41+Lin− MKPs, about 50 % of the cells were positive
for PIRB (Additional file 2: Fig. S4B). These findings
therefore suggest that the increased production of
platelets can be mediated by direct interactions be-
tween secreted Angptl4 and its receptor, expressed on
early MK-committed progenitor cells.
In contrast to MEPs, MKPs do not display any spleen
colony-forming activity [61]. The increase of megakaryo-
poiesis in the spleen after transplantation therefore de-
pends on the number of MEPs, trafficking from the
recovering bone marrow to the spleen. The fact that
after transplantation, Angplt4 increases relative cell
numbers of CD61+CD41low cells in the spleen but not in
the BM (Fig. 5) therefore most likely reflects the post-
transplant distribution of developing MKPs. In addition,
different effects of systemic available Angptl4 on the BM
and spleen cannot be excluded at this point.
After LPS injection, the TLR4−/− mice were shown to
have a decreased circulating and reticulated platelet
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platelets increased 1 week after a single-dose LPS injec-
tion, and this is beyond the time it takes for the circulat-
ing platelet pool to turnover in the mice [62]. As
platelets have no nuclei, these findings therefore suggest
a contribution of TLRs (direct or cytokine mediated) for
genomic regulation of platelet production at the level of
MKs. In support for this notion are findings which dem-
onstrate that inflammatory processes can increase MK
maturation and protein content through TLR2, which
may affect platelet function and thrombosis. In line with
this, our findings suggest that the increased production
of platelets during inflammation can be mediated by
direct interactions between secreted Angptl4 and its re-
ceptor, expressed on early MK-committed progenitor
cells.
The fact that after Angptl4 injection, an increase in im-
mature megakaryocytes and a lack of increase in mature
megakaryocytes lead to the production of platelets seems
to be counterintuitive at first sight. The in vitro differenti-
ation of CD61+CD41low MKs into platelet-producing
CD61+CD41high MKs has been demonstrated, and by
following the development of immature CD61+CD41low,
mature CD61+CD41high, and platelets for several days,
their in vivo dynamics after IL-11 injection suggested
that the subsequent increase in CD61+CD41high MKs
and platelets was due to de novo maturation from
CD61+CD41low MKs [33]. Conversely, we did not detect
any increase in CD61+CD41high-expressing MKs after
Angptl4 injection.
The accumulation of immature MKs could be either due
to an inhibition of the maturation of MKs by Angptl4, the
lack of local cytokines which promote terminal differenti-
ation of MKs, or alternatively a proapoptotic effect on ma-
ture MKs. For instance, a large number of mature
megakaryocytes that appear to undergo cell death as a re-
sult of IL-6 administration have been noted previously
[63], and at the same time, IL-6 has a platelet-enhancing
effect and promotes megakaryocyte maturation and colony
formation [64, 65]. In addition, both intrinsic and extrinsic
apoptosis pathways have been described to be implicated
in thrombopoiesis. The effects reported after Angptl4 in-
jection therefore may be directly or indirectly related to IL-
6 and be part of a homeostatic control mechanism, coun-
terbalancing megakaryocyte hyperplasia. As MK cells have
previously been shown to produce IL-6 [66], we measured
IL-6 levels in cytokine-supplemented cultures. After 9 days
of culture, the addition of Angptl4 or TPO increased IL-6
levels as compared to culture with SCF alone, with the
highest level recovered from combined Angptl4 and TPO
cultures (Additional file 2: Fig. S4C).
Furthermore, it has been shown that platelets express
PIRB as well as the ortholog of human leukocyte
immunoglobulin-like receptor B2 (LILRB2), and Angptl2has been shown to inhibit platelet activation partially
through the PIRB pathway [67].
In any case, large numbers of CD61+CD41low MKs, in-
duced by Angptl4, lead to their differentiation into
CD61+CD41high MKs and an increase in rapid platelet
recovery in vivo. This conclusion is strongly supported
by our in vitro findings: as shown in Fig. 6b, immature
CD61+CD41low/negative MK numbers are increased in
Angptl4-supplemented cultures and this leads to an
additive increase in mature CD61+CD41high MKs in
Angptl4- and TPO-combined cultures.
Angptl4 induces STAT3 protein expression in CD61
+CD41low/negative megakaryocytic lineage cells, and STAT3
has been suggested to be important for effective expansion
of megakaryocytic progenitor cells in the early stage of
megakaryopoiesis, as shown by the delayed recovery of
PLTs after myeloablation in mice carrying a dominant
negative version of STAT3 [47]. We here establish a
functional link between Angptl4 and STAT3 and
propose a model in which Angptl4 through regulation
of STAT3 expression expands immature MKs, which
in the setting of autologous stem cell transplantation
represents a potential approach to accelerate the re-
constitution of megakaryopoiesis.Conclusion
Based on the fact that single or combined deficiencies of
known hematopoiesis supporting cytokines do not abrogate
emergency hematopoiesis, we looked for inflammation-
induced cytokines with a yet unknown function in the
hematopoietic system. By identifying Angptl4, we provide a
new player with effects both on early hematopoietic
progenitors as well as on platelet production. We envi-
sion further studies aiming at a possible role of Angptl4
as a predictor of platelet engraftment after autologous
stem cell transplantation or its use in the acceleration
of engraftment in clinical transplantation settings.Additional files
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